Article info
Multiple sclerosis
Research paper
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
- Correspondence to Dr Bianca Weinstock-Guttman, Jacobs MS Center for Treatment and Research, 100 High Street, Buffalo, NY 14203, USA; bw8{at}buffalo.edu
Citation
Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
Publication history
- Received September 10, 2015
- Revised December 8, 2015
- Accepted December 9, 2015
- First published January 18, 2016.
Online issue publication
August 12, 2016
Article Versions
- Previous version (18 January 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/